EDR
ENDEAVOR GROUP HLDGS INC
No data for this timeframe.
Vol
Inst. Holders1 funds
Inst. Value$9.1M
Inst. Activity0 buys / 12 sells
Recent Activity
Inst.
STATE STREET CORP — EXIT
0 shares ($0.00)
Inst.
CHARLES SCHWAB INVESTMENT MANAGEMENT — EXIT
0 shares ($0.00)
Analyst Ratings
0Strong Buy
0Buy
6Hold
5Sell
1Strong Sell
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| BARCLAYS PLC | $9.1M | TRIM |
1 institutional holders with $9.1M total value (318,188 shares) as of 2025-Q3. Top holders: BARCLAYS.
Top Institutional Holders — 2025-Q3
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | BARCLAYS PLC | 318,188 | $9.1M | 100.0% | TRIM -64.1% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| STATE STREET CORP | EXIT | 1,366,411 | 0 | -100.0% | $0.00 | 2025-Q1 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | EXIT | 1,836,023 | 0 | -100.0% | $0.00 | 2025-Q1 |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | EXIT | 397,718 | 0 | -100.0% | $0.00 | 2025-Q1 |
| TUDOR INVESTMENT CORP ET AL | EXIT | 685,156 | 0 | -100.0% | $0.00 | 2025-Q1 |
| CANADA PENSION PLAN INVESTMENT BOARD | EXIT | 21,038,712 | 0 | -100.0% | $0.00 | 2025-Q1 |
| FIRST TRUST ADVISORS LP | EXIT | 2,640,849 | 0 | -100.0% | $0.00 | 2025-Q1 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | EXIT | 1,006,992 | 0 | -100.0% | $0.00 | 2025-Q1 |
| Pentwater Capital Management LP | EXIT | 15,121,666 | 0 | -100.0% | $0.00 | 2025-Q1 |
| FARALLON CAPITAL MANAGEMENT LLC | EXIT | 1,835,185 | 0 | -100.0% | $0.00 | 2025-Q1 |
| GABELLI FUNDS LLC | EXIT | 405,232 | 0 | -100.0% | $0.00 | 2025-Q1 |
| BlackRock, Inc. | EXIT | 4,231,465 | 0 | -100.0% | $0.00 | 2025-Q1 |
| TORONTO DOMINION BANK | EXIT | 9,242,739 | 0 | -100.0% | $0.00 | 2025-Q1 |
| TORONTO DOMINION BANK | NEW | — | 9,242,739 | — | $289.2M | 2024-Q4 |
| LMR Partners LLP | ADD | 4,393,759 | 6,508,403 | +48.1% | $203.6M | 2024-Q4 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | TRIM | 2,459,671 | 1,006,992 | -59.1% | $31.5M | 2024-Q4 |
| TUDOR INVESTMENT CORP ET AL | TRIM | 2,617,000 | 685,156 | -73.8% | $21.4M | 2024-Q4 |
| GABELLI FUNDS LLC | TRIM | 670,134 | 405,232 | -39.5% | $12.7M | 2024-Q4 |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | ADD | 317,038 | 397,718 | +25.4% | $12.4M | 2024-Q4 |
| BANK OF AMERICA CORP /DE/ | NEAR_EXIT | 1,607,302 | 207,747 | -87.1% | $6.5M | 2024-Q4 |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | DOUBLED | 24,014 | 189,276 | +688.2% | $5.9M | 2024-Q4 |
| MORGAN STANLEY | NEAR_EXIT | 7,473,284 | 170,761 | -97.7% | $5.3M | 2024-Q4 |
| Centiva Capital, LP | TRIM | 350,000 | 100,000 | -71.4% | $3.1M | 2024-Q4 |
| GROUP ONE TRADING LLC | DOUBLED | 30,586 | 87,073 | +184.7% | $2.7M | 2024-Q4 |
| CITIGROUP INC | TRIM | 176,973 | 77,547 | -56.2% | $2.4M | 2024-Q4 |
| MARSHALL WACE, LLP | TRIM | 187,234 | 75,765 | -59.5% | $2.4M | 2024-Q4 |
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
No SEC filing reports analyzed yet. Reports are generated when new filings are detected and processed by the LLM pipeline.
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution: 0% buy across 12 analysts — 0 strong buy, 0 buy, 6 hold, 5 sell, 1 strong sell. No current recommendation available.
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Mar 1, 2025 | 0 | 0 | 6 | 5 | 1 | 0% | |
| Feb 1, 2025 | 0 | 0 | 7 | 4 | 1 | 0% | |
| Jan 1, 2025 | 2 | 4 | 7 | 0 | 0 | 46% | |
| Dec 1, 2024 | 2 | 4 | 7 | 0 | 0 | 46% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
No events recorded for this ticker. Events include FDA actions, clinical trials, enforcement actions, and market-moving developments.